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Abstract
The phenotypic methods for identiﬁcation of antifungal resistance are reliable procedures, and MIC determination by reference techniques
is the gold standard to detect resistant clinical isolates. In recent years, progress has been made towards the description of resistance
mechanisms at molecular level. There are methods of detection that can be useful for clinical laboratories, but lack of standardization
precludes their full and effective integration in the routine daily practice. The molecular detection of Candida resistance to azoles and to
echinocandins and of Aspergillus resistance to triazoles can be clinically relevant and could help to design more efﬁcient prevention and
control strategies. This text reviews the present state of the detection of mechanisms of resistance at the molecular level in Candida spp.
and Aspergillus spp. and its relevance to clinical practice.
Keywords: Aspergillus, Candida, mutations, mycosis, tandem repeat
Article published online: 21 December 2013
Clin Microbiol Infect 2014; 20 (Suppl. 6): 54–59
Corresponding author: M. Cuenca-Estrella, Spanish National
Center for Microbiology, Ctra. Majadahonda-Pozuelo Km2,
Majadahonda, Madrid 28220, Spain
E-mail: mcuenca-estrella@isciii.es
Introduction
The standardization of antimicrobial susceptibility testing
(AST) is a long process that must comply with several
requirements. To this end, it is essential to develop reliable
reference procedures. Antifungal susceptibility testing has
been standardized in last two decades, and it is still under
development for some compounds and fungal species [1,2].
There are two standards for antifungal susceptibility testing
both based largely on broth microdilution methods: One
created by the European Committee on Antibiotic Suscepti-
bility Testing (EUCAST) and the other one created by the
Clinical Laboratory Standard Institute (CLSI, former NCCLS).
Both organisations have led standardization processes, have
performed reproducibility studies and recommended methods
for quality control assurance [2–5].
In addition, the EUCAST and the CLSI have developed
breakpoints and epidemiological cut-off values (ECVs) that are
now established for Candida spp. and Aspergillus spp. [6–9]. The
procedure to develop interpretative breakpoints is a multistep
process based on the analysis of the MIC distributions and the
clinical relationship between MIC values and efﬁcacy. There
are currently available breakpoints to interpret AST results of
amphotericin B, azoles and echinocandins for Candida and
amphotericin B and azoles for Aspergillus.
After standardization of AST and setting breakpoints,
reliable but more practical techniques of AST should be
validated for use in clinical laboratories as the dilution standard
reference procedures are rather complex methods for routine
susceptibility testing [1,10]. There are several commercial and
disc diffusion techniques that exhibit a high correlation with
results of reference procedures and that are already used in
many clinical laboratories. The extended use of AST methods
has deﬁned the prevalence of strains with high MIC values and
some resistance mechanisms at the molecular level [11,12]. A
number of molecular studies are currently in progress to
ascertain the frequency of these mutants among wild-type
populations [13,14]. The results of those surveys could be very
useful to design strategies of prevention and control of
emergence of resistance.
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This text reviews the present situation of the detection of
mechanisms of resistance at the molecular level in Candida spp.
and Aspergillus spp. and their relevance to the clinical practice.
The reliability of molecular tools for the detection of
resistance is also analysed as well as their performance to
monitor the incidence of mutants with resistance to antifungal
agents.
Detection of Molecular Resistance to
Amphotericin B
Table 1 shows stages of the standardization process of AST by
antifungal agent and by fungal species. In the case of
amphotericin B, the system for MIC determination is able to
detect strains exhibiting high MIC values [15]. Several studies
reported, however, that reference procedures are not com-
pletely reliable to classify correctly some amphotericin
B-resistant strains [16]. The reference techniques yield a
range of amphotericin B MIC values that spans only three of
four twofold serial dilutions precluding reliable discrimination
between susceptible and resistant populations. Nevertheless,
as some rare isolates were described as intrinsically resistant
to the polyenes and they exhibit very high amphotericin B MIC
values, breakpoints were proposed and set for Candida and
Aspergillus some years ago [5,17].
Resistance to amphotericin B is an uncommon phenomenon
in Candida (1–3%) and Aspergillus, although a proportion of
A. terreus and A. ﬂavus has higher MIC values [13,15,18].
Because the shortage of clinical strains with resistance to
amphotericin B, not many studies on the molecular description
of resistance mechanisms have been reported. It has been
published that resistance is associated with mutants with low
levels of ergosterol and disturbances of levels and composition
of phospholipids in the membrane. Some of these changes have
been associated with mutations in genes ERG2, ERG3 and
ERG11. In addition, the polyenes induce oxidative stress in
fungal cells, and resistant isolates can have higher levels of
antioxidative enzymes and/or alterations in the production of
free radicals [19–22].
Table 2 shows a summary of the current state of the
molecular detection of resistance mechanisms by antifungal
compound and by Candida and Aspergillus species, from the
point of view of clinical laboratories. Determining resistance
mechanisms of amphotericin B at the molecular level is
clinically irrelevant. The number of strains exhibiting resistance
in vitro is low, and mutants harbouring DNA changes related to
rises in the MIC value of amphotericin B are hardly ever found
in clinical samples [11,15]. There are no reliable molecular
tools to detect amphotericin B resistance. Some reports have
included ergosterol quantiﬁcation or determinations of cata-
lase activity and production of free radicals, but these
procedures are phenotypic techniques that have not been
standardized so far [23]. It can be concluded that currently
molecular determination of amphotericin B resistance is not
more useful than MIC determination for susceptibility testing
and for the management of patients. Molecular detection is not
TABLE 1. Current situation of the antifungal susceptibility testing ﬁeld by antifungal agent, by species and by stages of
standardization process
Antifungal
agents
Fungal
species
Availability of
reference
procedures
Breakpoint
setting
Integration of AST in clinical
laboratories in routine daily
practice
Molecular
description
of resistance
Prevention and control
strategies to avoid
emergence of resistance
Amphotericin B Candida spp. Yes Yes Yes Noe No
Aspergillus spp Yes Yesb Yes No No
Azoles Candida spp. Yes Yesc Yes In progress No
Aspergillus spp Yes Yesb Yes In progress No
Echinocandins Candida spp. Yes Yesd Yes In Progress No
Aspergillus spp Yesa No In Progress No No
aNo totally standardized yet for testing ﬁlamentous fungi.
bThe Clinical Laboratory Standard Institute (CLSI) has not proposed yet breakpoints for Aspergillus.
cThe CLSI has not proposed posaconazole breakpoints for Candida.
dThe European Committee on Antibiotic Susceptibility Testing is in process of setting caspofungin breakpoints for Candida.
eIrrelevant as number of resistant mutants is very low.
TABLE 2. Current situation of the molecular detection of
resistance mechanisms by antifungal compound and by
species from the point of view of clinical laboratories
Antifungal
agents
Fungal
species
Clinical
relevance of
molecular
testing
Availability
of reliable
molecular
tools
Integration
in routine
daily
practice
Amphotericin B Candida spp. No No No
Aspergillus spp. Noa No No
Azoles Candida spp. Yes Yes Possible
Aspergillus spp. Yes Yes Possible
Echinocandins Candida spp. Yes Yes Possibleb
Aspergillus spp. No No No
aSome strains of A. terreus exhibit high MIC values of amphotericin B, and it could
have clinical relevance.
bA signiﬁcant number of resistance mechanisms are still unknown, and number of
resistant strains is low.
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a reliable approach to design strategies of prevention and
control of resistance to amphotericin B.
Detection of Molecular Resistance to Azole
Agents
It has been proven that strains and species exhibiting high MIC
values to azoles are unlikely to respond to treatments with
azoles. Breakpoints to interpret the results of testing are
available by both CLSI (for Candida only) and EUCAST (for
some species of Candida and Aspergllus). They are species
speciﬁc and are periodically revised [2,6,7,24].
Resistance to azole agents has been described quite
commonly in Candida spp. Candida glabrata, a species with
decreased susceptibility to ﬂuconazole and other triazoles, is
the second most common cause of invasive candidiasis in many
countries and geographical areas. Candida krusei is the ﬁfth
cause of candidemia and seems to be insensible to ﬂuconazole.
Resistance has been also found in C. albicans, C. tropicalis and
C. parapsilosis. Several population-based surveys of invasive
candidiasis have reported rates of resistance to ﬂuconazole
between 10% and 25%. Many of these ﬂuconazole-resistant
isolates have cross-resistance to other azole agents [14,15].
Resistance to triazoles is not common in Aspergillus spp.,
being estimated below 5% in most of countries [13,25–27].
However, triazole resistance in A. fumigatus appears to be
increasing in several European countries in recent years. It has
been proposed that resistance has evolved in the environment
under the selective pressure of azole fungicides widely used for
crop protection and material preservation in Europe [27,28].
Antifungal susceptibility testing of azole agents is highly
recommended for patient management in the ESCMID
Guideline for the Management and Diagnosis of Candida
Diseases 2012 [6].
The target of the azoles is the 14-alpha lanosterol demethyl-
ase enzyme generated by the gene ERG11 in yeasts and the
CYP51 in ﬁlamentous fungi. Several genetic disturbances have
been related to azole resistance. In the case of Candida,
resistance is largely caused by overexpression of genes that
code efﬂux pumps. The overexpression increases the capability
of the fungal cell of expelling harmful substances such as
antifungal agents. Mutants harbouring alterations in the ABC
pumps (ATP binding cassette), the MFS pumps (major facilitator
superfamily) or both have been found. In addition, mutations of
ERG11 have been related to disturbances in the tridimensional
structure of the protein, which can cause alterations in the site
of docking between the demethylase and the antimicrobial agent
increasing the MIC values. Other genetic changes such as
chromosomal duplication, genetic conversion and mitotic
recombination have been also associated with azole resistance
in Candida. It should be noted that several of mechanisms
described above can coexist in the same fungal cell, a phenom-
enon observed in some isolates after long-term therapy (several
months) with azoles [29–31].
Mechanisms of resistance to triazoles in Aspergillus spp.
were described some years ago [32,33]. The identiﬁcation and
sequencing of two different sterol demethylase genes (CYP51A
and CYP51B) in A. fumigatus led experts to describe mutations
in the CYP51A responsible for resistance in vitro to azoles [34].
The point mutations cause structural changes in the active site
of the demethylase, decreasing the afﬁnity to its ligands [35]. A
number of mutations have been described and related with
different proﬁles of resistance in Aspergillus. Mutations in some
codons of CYP51A have been associated with resistance to
itraconazole and posaconazole, and changes in other codons
(220) to cross-resistance to all triazoles [32,33,36,37]. The
mutation L98H coupled with a duplication of a fragment of
DNA sequence in the promoter of CYP51A (also known as
tandem repeat) has been proven to upregulate the expression
of the enzyme, increasing eight times its ability to function and
causing resistance to the azoles [38]. Resistance due to the
tandem repeat has been linked to the use of azole fungicides in
agriculture and gardening [27,28,39]. The resistance due to
point mutations is related to long-term treatments with azoles.
It has been described in patients suffering from chronic lung
diseases treated with itraconazole as prophylaxis or empirical
therapy [26]. Resistance to triazoles has been also described in
A. ﬂavus and A. terreus, but it is an uncommon phenomenon
[13,40,41].
It seems that the gene coding the azole target cyp51A could
be a hotspot for mutations that confer phenotypic resistance
and that selective pressure with triazoles and pesticides can
result in increasing numbers of resistant isolates [42,43].
Recently, the link between pesticides and azole resistance has
been described also in C. tropicalis, although further studies
should be carried out to verify this environmental hypothesis
[44].
Regarding the clinical relevance of determining molecular
mechanisms of resistance to azoles, it should be noted that the
underlying mechanism remains unknown in a number of
resistant isolates. Some new mechanisms such as increase in
expression and mutations related to efﬂux pumps and
mutations in the CCAAT-binding transcription factor complex
subunit HapE have been reported in Aspergillus [42,45–47].
However, the prevalence of resistant strains and their
correlation with clinical failures make clinically relevant the
molecular description of resistance. The probable link to
selective pressure due to prophylactic treatments and pesti-
cides suggests that some strategies of prevention and control
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could be already implemented. The main concerns about
molecular determination of azole resistance are lack of
standardization of techniques of detection. MIC determination
is still the most reliable procedure for surveillance of clinical
isolates, but molecular methods allowing detection of resis-
tance also in culture-negative specimens must be further
developed and propagated [26].
Detection of Molecular Resistance to
Echinocandins
Resistance to echinocandins is not common among clinical
isolates of Candida and Aspergillus. [14,15]. Candida spp. are
susceptible to the three compounds licensed although C. par-
apsilosis exhibits higher MIC values to echinocandins due to a
naturally occurring amino acid change in its Fks1, a glucan
synthase, the target of these antifungal agents [48]. However,
the reduced echinocandin susceptibility of C. parapsilosis does
not appear to have clinical relevance. Aspergillus spp. are also
susceptible in vitro to echinocandins.
The procedures of AST of echinocandins are able to
detect high MIC values in yeasts, and these resistant isolates
in vitro have been related to clinical failures and breakthrough
invasive mycosis in patients receiving echinocandins [49].
Species-speciﬁc breakpoints have been proposed to interpret
the results of AST of echinocandins in Candida. The CLSI has
set breakpoints for Candida spp. and the three echinocandins
and the EUCAST for anidulafungin and micafungin so far [3,5].
Unlike yeasts, the AST systems currently available do not
yield reliable results to evaluate the activity in vitro of
echinocandins against Aspergillus and other moulds [4]. The
echinocandins inhibit only partially the growth in vitro of
ﬁlamentous fungi. Experts recommend the use the minimal
effective concentration (MEC) in an attempt to address the
problem, but MEC determination is a subjective procedure.
As a result, breakpoints for AST of ﬁlamentous fungi have
not been set. There are some ECVs available, but it is not
clear yet if they can be used to interpret the AST results
[1,2,11].
The rate of resistance to echinocandins in most of species
of Candida is very low. However, there are reports describing
clinical cases with echinocandin-resistant isolates [50–52].
Several resistance mechanisms to echinocandins have been
published. There are adaptive stress responses that result in
elevated cell wall chitin content and natural amino acid changes
that confer elevated MIC values. Some of isolates with high
MIC values associated with clinical failures, which have been
molecularly analysed, harboured a mutation in the FKS1 gene.
There are two hotspots in this gene, and a number of mutations
that confer reduced glucan synthase sensitivity have been
published [12,53].
Table 2 shows a summary of the current situation of the
molecular detection of resistance for clinical laboratories.
Determining resistance mechanisms of echinocandins at the
molecular level may have some relevance. The number of
Candida strains exhibiting resistance in vitro is low, but there
are already available lists of mutations causing resistance in vitro
to these compounds. In addition, there are reliable molecular
tools to detect echinocandin resistance although standardiza-
tion and external party validation should be done before
recommending for clinical use. The extended use of echino-
candins in daily clinical practice and the presence of the
hotspots lead to the conclusion that echinocandin resistance
could be an emerging problem in yeasts, and therefore,
epidemiological surveillance of molecular resistance could be
very useful soon to design prevention programmes. However,
it should be noted that currently molecular detection of
echinocandin resistance is not more useful than MIC deter-
mination for knowing the incidence of resistant strains and for
the management of patients. Regarding ﬁlamentous fungi,
further efforts should be taken to improve the reliability of
AST and then to analyse the prevalence of resistance at
molecular level.
Conclusions
The phenotypic methods for identiﬁcation of antifungal resis-
tance are reliable, and MIC determination by reference
procedures is the gold standard to detect resistant clinical
isolates. In recent years, progress has been made towards the
description of resistance mechanisms at molecular level. There
are methods of detection that can be useful for clinical
laboratories, but lack of standardization precludes their full and
effective integration in the routine daily practice. Multicentre
studies including third party validation and reproducibility
assessment should be designed. The molecular detection of
Candida resistance to azoles and to echinocandins and of
Aspergillus resistance to triazoles can be clinically relevant and
could help to design more efﬁcient prevention and control
strategies. New automated and massive sequencing technique
could change AST procedures in the upcoming years.
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